Logo image of ALMS

ALUMIS INC (ALMS) Stock Fundamental Analysis

USA - NASDAQ:ALMS - US0223071020 - Common Stock

4.44 USD
-0.09 (-1.99%)
Last: 10/10/2025, 9:09:47 PM
4.37 USD
-0.07 (-1.58%)
After Hours: 10/10/2025, 9:09:47 PM
Fundamental Rating

3

Overall ALMS gets a fundamental rating of 3 out of 10. We evaluated ALMS against 196 industry peers in the Pharmaceuticals industry. ALMS has a great financial health rating, but its profitability evaluates not so good. ALMS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALMS has reported negative net income.
In the past year ALMS has reported a negative cash flow from operations.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ALMS has a Return On Assets of -37.24%. This is comparable to the rest of the industry: ALMS outperforms 46.94% of its industry peers.
The Return On Equity of ALMS (-46.88%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.24%
ROE -46.88%
ROIC N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALMS has more shares outstanding
There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

ALMS has an Altman-Z score of -0.84. This is a bad value and indicates that ALMS is not financially healthy and even has some risk of bankruptcy.
ALMS has a Altman-Z score (-0.84) which is in line with its industry peers.
There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.84
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

ALMS has a Current Ratio of 6.05. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.05, ALMS is doing good in the industry, outperforming 72.96% of the companies in the same industry.
ALMS has a Quick Ratio of 6.05. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALMS (6.05) is better than 72.96% of its industry peers.
Industry RankSector Rank
Current Ratio 6.05
Quick Ratio 6.05
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ALMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.89%.
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.5%
EPS Next 2Y27.87%
EPS Next 3Y18.7%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 5M 10M 15M 20M 25M
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

ALMS's earnings are expected to grow with 18.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y18.7%

More info and screens

0

5. Dividend

5.1 Amount

ALMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALUMIS INC

NASDAQ:ALMS (10/10/2025, 9:09:47 PM)

After market: 4.37 -0.07 (-1.58%)

4.44

-0.09 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11
Inst Owners47%
Inst Owner Change0%
Ins Owners0.83%
Ins Owner Change41.33%
Market Cap462.03M
Analysts87.14
Price Target19.38 (336.49%)
Short Float %3.75%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.82%
Min EPS beat(2)-20.07%
Max EPS beat(2)-19.57%
EPS beat(4)1
Avg EPS beat(4)10.41%
Min EPS beat(4)-20.07%
Max EPS beat(4)83.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.66%
EPS NY rev (1m)22.32%
EPS NY rev (3m)37.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.97%
Revenue NY rev (1m)10.9%
Revenue NY rev (3m)273.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.04
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-5.46
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.32
OCFYN/A
SpS0.19
BVpS4.66
TBVpS4.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.24%
ROE -46.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.72%
Cap/Sales 8.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.05
Quick Ratio 6.05
Altman-Z -0.84
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.73%
EPS Next Y70.5%
EPS Next 2Y27.87%
EPS Next 3Y18.7%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.49%
EBIT Next 3Y-4.33%
EBIT Next 5YN/A
FCF growth 1Y-90.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.25%
OCF growth 3YN/A
OCF growth 5YN/A